Immunic Stock Jumps After Pricing $400 Million Private Placement
Immunic Inc (NASDAQ:IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.
- Immunic stock is gaining positive traction. Why are IMUX shares climbing?
A Look At The Deal
The financing was led by existing investor BVF Partners and included a strong lineup of institutional backers such as OrbiMed, RA Capital, Janus Henderson, Avidity Partners and EcoR1 Capital.
The structure provides $200 million upfront through pre‑funded warrants priced at 87 cents each, with the potential for another $200 million if accompanying warrants are exercised. Those warrants expire either 30 days after top‑line Phase 3 ENSURE data is released or in February 2031, whichever comes first.
How Immunic Plans To Use The Cash
The new capital is expected to fund Immunic through late 2027 and support several major priorities. A large portion will go toward completing the Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis, with top‑line data still expected by the end of 2026. If the results are positive, the company plans to file for approval in mid‑2027 and is targeting a potential regulatory green light in 2028.
The financing will also allow Immunic to launch a Phase 3 program in primary progressive multiple sclerosis (PPMS) later this year, a study that is expected to run for roughly three and a half to four years.
IMUX Price Action: Immunic shares were up 26.43% at $1.10 at the time of publication on Friday.
Image: Zakharchuk/Shutterstock.com
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wall Street giants’ trading operations show a tale of two extremes: JPMorgan (JPM.US) expects a surge in Q3 performance, while Bank of America (BAC.US) warns of a slowdown
JPMorgan predicts that trading and investment banking income will see double-digit growth in Q3, triggering a rebound in its stock price. Previously, Bank of America warned of flat revenue due to a pullback in financing, leading to a sell-off in the sector.
Trillion-dollar defense budget in sight, Guggenheim strongly recommends defense stocks, L3Harris Technologies (LHX.US) is the top large-cap pick
Guggenheim Securities recently initiated coverage of 22 aerospace and defense companies, with an overall positive outlook on defense contractors and aircraft manufacturers, but a cautious attitude toward commercial aviation aftermarket suppliers.
Tokenized funds expand across chains, yet liquidity remains fragmented – Why?
Japan Reportedly Plans to Double Defense Spending to 3.5% of GDP, Ministry of Defense Denies, Yet Japanese Bond Yields Hit 30-Year High
According to reports, Japanese defense officials have expressed their willingness to significantly increase defense spending during meetings with the United States. One proposal is to raise defense spending to 3.5% of GDP within ten years, while another, lower target is 3%. Japanese officials previously stated that this fiscal year's defense and related expenditures are approximately $68.8 billion, equivalent to about 1.9% of Japan's nominal GDP in 2022.
Crypto prices
More
